Data / Drug companies / Methylphenidate hydrochloride
Methylphenidate hydrochloride: 39 companies and 211 products in the FDA NDC directory
Methylphenidate hydrochloride is listed in the FDA National Drug Code Directory by 39 companies, with 211 products in commercial distribution. 156 of the products (73.9%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, extended release; capsule, extended release; tablet, and the newest product started marketing on February 1, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 39
- Products
- 211
- Generic (ANDA) products
- 156 (73.9%)
- Application numbers
- 46
- Controlled substance schedule
- Schedule II
- Routes
- Oral
- Brand names
- Metadate CD, Relexxii, Jornay PM Extended-Release, Quillivant XR, Concerta, QuilliChew Er, Ritalin, Methylphenidate
- openFDA record search
- api.fda.gov
Companies that list methylphenidate hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Lannett Company, Inc. | 16 | capsule, extended release; tablet, extended release | New drug applications (NDA) | February 22, 2024 |
| Bryant Ranch Prepack | 14 | tablet; solution | Generic drugs (ANDA) | April 16, 2024 |
| SpecGx LLC | 14 | capsule, extended release; tablet, extended release | Generic drugs (ANDA) | September 29, 2015 |
| Camber Pharmaceuticals, Inc. | 10 | tablet, extended release; tablet, chewable | Generic drugs (ANDA) | September 3, 2019 |
| XLCare Pharmaceuticals, Inc. | 10 | tablet, extended release; tablet, chewable | Generic drugs (ANDA) | February 26, 2020 |
| Amneal Pharmaceuticals of New York LLC | 9 | capsule, extended release; tablet | Generic drugs (ANDA) | September 20, 2016 |
| Lupin Pharmaceuticals,Inc. | 8 | tablet, chewable; tablet | Generic drugs (ANDA) | January 20, 2016 |
| Actavis Pharma, Inc. | 7 | capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Granules Pharmaceuticals Inc. | 7 | capsule, extended release; tablet, extended release | Generic drugs (ANDA) | September 10, 2019 |
| NextWave Pharmaceuticals, Inc | 7 | suspension, extended release; tablet, chewable, extended release | New drug applications (NDA) | April 18, 2016 |
| Rhodes Pharmaceuticals LLC | 7 | capsule, extended release | Authorized generics (NDA) | April 1, 2020 |
| Trigen Laboratories, LLC | 7 | tablet, extended release | Generic drugs (ANDA) | June 23, 2022 |
| Vertical Pharmaceuticals, LLC | 7 | tablet, extended release | New drug applications (NDA) | June 23, 2022 |
| Aytu BioPharma, Inc. | 6 | capsule, extended release | New drug applications (NDA) | February 22, 2024 |
| Golden State Medical Supply, Inc. | 6 | tablet, extended release | Generic drugs (ANDA) | November 21, 2018 |
| Ascend Laboratories, LLC | 5 | tablet; solution | Generic drugs (ANDA) | April 1, 2020 |
| Dr. Reddy's Laboratories Inc. | 5 | capsule, extended release | Generic drugs (ANDA) | December 20, 2024 |
| Ironshore Pharmaceuticals Inc. | 5 | capsule | New drug applications (NDA) | June 1, 2019 |
| KVK-Tech, Inc. | 5 | tablet; solution | Generic drugs (ANDA) | May 11, 2017 |
| Actavis Pharma, Inc. | 4 | tablet, film coated, extended release | Generic drugs (ANDA) | March 4, 2019 |
| American Health Packaging | 4 | tablet, extended release | Generic drugs (ANDA) | June 25, 2020 |
| Janssen Pharmaceuticals, Inc. | 4 | tablet, extended release | New drug applications (NDA) | August 1, 2000 |
| Lannett Company, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | September 23, 2013 |
| Sun Pharmaceutical Industries, Inc. | 4 | tablet; tablet, extended release | Generic drugs (ANDA) | December 20, 2024 |
| Accord Healthcare Inc. | 3 | tablet | Generic drugs (ANDA) | December 23, 2020 |
| Aurolife Pharma, LLC | 3 | tablet | Generic drugs (ANDA) | April 11, 2017 |
| Bryant Ranch Prepack | 3 | solution; tablet | Generic drugs (ANDA) | March 29, 2019 |
| Nivagen Pharmaceuticals, Inc. | 3 | tablet | Generic drugs (ANDA) | April 16, 2024 |
| Rising Pharma Holdings, Inc. | 3 | tablet, chewable | Generic drugs (ANDA) | December 18, 2018 |
| Sandoz Inc | 3 | tablet | New drug applications (NDA) | December 31, 1955 |
| Solco Healthcare US, LLC | 3 | tablet | Generic drugs (ANDA) | July 1, 2020 |
| American Health Packaging | 2 | tablet | Generic drugs (ANDA) | September 30, 2014 |
| Ascent Pharmaceuticals, Inc. | 2 | solution | Generic drugs (ANDA) | January 29, 2021 |
| Bryant Ranch Prepack | 2 | tablet | Generic drugs (ANDA) | April 16, 2024 |
| Cranbury Pharmaceuticals, LLC | 2 | solution | Generic drugs (ANDA) | March 4, 2015 |
| Eywa Pharma Inc | 2 | solution | Generic drugs (ANDA) | March 29, 2019 |
| Quagen Pharmaceuticals LLC | 2 | solution | Generic drugs (ANDA) | June 4, 2020 |
| Shionogi Inc. | 2 | solution | New drug applications (NDA) | December 19, 2002 |
| NorthStar RxLLC | 1 | tablet, extended release | Generic drugs (ANDA) | February 1, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 55 | 26.1% |
| Capsule, extended release | 54 | 25.6% |
| Tablet | 51 | 24.2% |
| Solution | 22 | 10.4% |
| Tablet, chewable | 13 | 6.2% |
| Capsule | 5 | 2.4% |
| Suspension, extended release | 4 | 1.9% |
| Tablet, film coated, extended release | 4 | 1.9% |
| Tablet, chewable, extended release | 3 | 1.4% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 156 | 73.9% |
| New drug applications (NDA) | 40 | 19% |
| Authorized generics (NDA) | 15 | 7.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| Central Nervous System Stimulant | 211 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.